Skip to Content

Daiichi Sankyo Co Ltd ADR DSNKY Stock Quote

| Rating as of


Last close prices updated as of Jan 31, 2023, 6:21 PM EST | USD
  • Last Close 31.4
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Growth
  • Day Range 30.94  –  31.49
  • Year Range 19.39  –  34.87
  • Market Cap 60.1871 Bil
  • Volume / Avg 37,485.0 /  66,141.9
  • Price / Sales 7.27
  • Price / Book 5.56
  • Forward Div Yield 0.67%
  • Trailing Div Yield 0.67%

Morningstar‘s Stock Analysis DSNKY

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics DSNKY

Company Profile DSNKY

Business Description

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), and HER3-DXd (HER3). Enhertu entered the clinic in 2015 and received its first U.S Food and Drug Administration approval in December 2019 for third-line late-stage HER2-positive breast cancer and its high efficacy is changing the treatment landscape for HER-expressing breast cancers. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

3-5-1, Nihonbashi-honcho, Chuo-ku
Tokyo, 103-8426, JPN
Industry Drug Manufacturers - General
Employees 16,458

FAQs for Daiichi Sankyo Co Ltd ADR Stock

No. DSNKY does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

DSNKY’s market cap is 60.19 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

DSNKY’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

DSNKY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare DSNKY’s historical performance against its industry peers and the overall market.